ArticleOncogene2006
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02303899 (A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Treatment Modalities for Refractory-Recurrent Tenosynovial Giant Cell Tumor (TGCT): An Update.Medicina (Kaunas, Lithuania) · 2024Review
- Mcl-1 Protein and Viral Infections: A Narrative Review.International journal of molecular sciences · 2024Review
- Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors.Journal of bone oncology · 2022Article
- Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes.Clinical and experimental immunology · 2019Article
- Article
- Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.Current treatment options in oncology · 2016Review
- Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT.PloS one · 2016Article
- Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?European journal of nuclear medicine and molecular imaging · 2015Article
- Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats.PloS one · 2015Article
- Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants.Iranian journal of basic medical sciences · 2014Article
- Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.PloS one · 2014Article
- Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).International journal of clinical and experimental pathology · 2014Article
- Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Arterial colony stimulating factor-1 influences atherosclerotic lesions by regulating monocyte migration and apoptosis.Journal of lipid research · 2010Article
- PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2.Nature medicine · 2010Article
- A potential role for colony-stimulating factor 1 in the genesis of the early endometriotic lesion.Fertility and sterility · 2010Article
- Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.Sarcoma · 2010Article
- Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes.Arthritis research & therapy · 2010Article
- Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.Leukemia · 2009Article
- Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis.Leukemia · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kinase inhibitor imatinib is used in the treatment of chronic myeloid leukaemia, where it targets the intracellular Bcr-Abl tyrosine kinase, and gastrointestinal stromal tumours, where it targets either the KIT or PDGF tyrosine kinase receptors. Here, we report that imatinib is also an effective inhibitor of the closely related FMS receptor for macrophage colony stimulating factor and that mutation of Asp 802 of FMS to Val confers imatinib resistance. Imatinib readily reverted the transformed phenotype of haemopoietic and fibroblast cell lines that express the oncogene v-fms and also inhibited the growth of the Bacl.2F5 macrophage cell line. The cellular IC50 value of imatinib for FMS was similar to those for Bcr-Abl and KIT. Consequently, imatinib may also prove effective for the treatment of diseases whose progression is dependent upon macrophage-colony stimulating factor, this includes certain aspects of cancer and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.